glp-1 and ssri receptor agonists GLP-1 Medications – Community Education

Guidance for industry: diabetes mellitusevaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes

Behavior change and drug combinations seem to be a good starting point for further companion offers

Type 2 diabetes (though it's not yet approved for this use) : In the phase 3 ACHIEVE-1 trial, adults with early type 2 diabetes who took orforglipron experienced a drop in their A1C from 8% to 6.5%6.7% after 40 weeks

R.WongC

Research Citations & Literature GLP-1 Receptor Agonism : Sema and Cardiovascular Outcomes in Patients with Type 2 Diabetes Metabolic Signaling : Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes Weight Regulation Mechanisms : Effects of Sema on appetite and energy intake Need a higher dose

As someone managing diabetes and cardiometabolic disease daily, this is the shift from reactive glycemic control to proactive cardiovascular and renal protection